Introducing the Emulate Monthly Newsletter! For the first edition, explore the key highlights from August, and get a sneak preview at exciting upcoming events.
Emulate, Inc.’s Post
More Relevant Posts
-
The Gold standard ’omics for the Research community 🎯 Global Academic Collaboration 🌍 Nightingale Health 🩸
Webinar alert! 🎓 Join us tomorrow for an enlightening webinar on urine metabolomics! 🎓 The applications of our urine biomarker analysis include the early detection and prognosis of both type 1 and type 2 diabetes, along with associated diabetic complications, such as kidney disease. It also facilitates a molecular-level understanding of cardiometabolic risk factors, including adiposity and body fat distribution, allowing scientists to unravel their roles in disease etiology. You can register here 👇🏼 #HealthTech #Metabolomics #PrecisionMedicine #NightingaleHealth #Research #ScientificStudy #Webinar
Our webinar by Peter Würtz is tomorrow! Remember to sign up and join us on 7th May at 2 p.m. CEST! Learn more about the webinar and sign up: https://lnkd.in/eAFSgrE7
Urine metabolomics by Nightingale NMR - consistent biomarkers for cardiometabolic disease and underlying risk factors across cohorts
lyyti.fi
-
Submit your article to our Special Issue!
Nanoparticles for Cancer Immunotherapy: from Basics to Clinics
frontiersin.org
-
Check out this article I was featured in.
This Is What It’s Like to Live With Multiple Myeloma
prevention.com
-
Senior Scientist & Director of Translational Cancer Research Facility at the National Center for Cancer Care & Research (HMC) Clinical Professor of Biomedical Sciences, College of Health Sciences, Qatar University
I would like to share with you this updated review we have published today. In this review, we aim to provide updated immunological insight on the mechanism of action, expression, and the clinical application of immune cells' stimulatory and inhibitory molecules as prognostic and predictive biomarkers in HNC. The review is focused mainly on CD27 and CD137 (members of the TNF-receptor superfamily), natural killer group 2 member D (NKG2D), tumor necrosis factor receptor superfamily member 4 (TNFRSF4 or OX40), S100 proteins, PD-1, PD-L1, PD-L2, T cell immunoglobulin and mucin domain 3 (TIM-3), cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), indoleamine-pyrrole 2,3-dioxygenase (IDO), B and T lymphocyte attenuator (BTLA). It also highlights the importance of T, natural killer, and antigen-presenting cells as robust biomarker tools for understanding immune checkpoint inhibitor-based treatment dynamics. Though a comprehensive review, all aspects of the immune molecules could not be covered as they were beyond the scope of the review; Further review articles can cover other aspects to bridge the knowledge gap.
The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
sciencedirect.com
-
Professor of Genetics-Deputy Director -Institute of Biological and Chemical Systems-Functional Molecular Systems (IBCS-FMS), KIT
Check out our new review on:
CD44: A Stemness Driver, Regulator and Marker – all in one?
academic.oup.com
-
I share my recent publication.
The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis
mdpi.com
-
Inviting you to read our latest article
Targeting BCL-2 family proteins using BH3 mimetic drugs for cancer therapy: A systematic review of randomized clinical trials
sciencedirect.com
-
Chair of Breast Cancer Surgery @ The London Breast Institute | Consultant Oncoplastic Breast Surgeon
Our latest publication
Reevaluating Axillary Lymph Node Dissection in Total Mastectomy for Low Axillary Burden Breast Cancer: Insights from a Meta-Analysis including the SINODAR-ONE Trial - PubMed
pubmed.ncbi.nlm.nih.gov
-
Invited Assistant Professor (University Teacher) at Faculdade de Medicina da Universidade de Lisboa
Sharing our recent publication!
The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis
sciencedirect.com
